Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
-
REGULATORY Report Systems for Improper Drug Promotion Little-Known among Pharmacists: MHLW Study
June 16, 2021
-
REGULATORY Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
-
BUSINESS Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
-
BUSINESS Shipment Curbs of 3,000-Plus Products Taking a Toll on Wholesalers as Generic Woes Continue
June 15, 2021
-
ORGANIZATION Saitama-Based Hospital Group Introduces Formulary in 18 Therapeutic Areas, Aims to Spread Know-How in Region
June 15, 2021
-
ORGANIZATION FPMAJ Drug Price Report Rebuts Issues Raised over Cost-Plus Method, PMP and More
June 14, 2021
-
BUSINESS Japan Approves 1st Oncolytic Virus, Delytact, for Malignant Glioma
June 14, 2021
-
REGULATORY LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
-
BUSINESS Eisai CEO Says Aducanumab Price Tag Reflects Its Value, 1 Million Patients Estimated in Japan
June 10, 2021
-
REGULATORY Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
-
BUSINESS Aducanumab Gets Accelerated OK, Expert Says FDA Verdict Would Affect Japan Review Too
June 9, 2021
-
REGULATORY Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
-
BUSINESS Japan Drug Makers Derive Near-60% of FY2020 Sales Overseas as Home Market Falters: Tally
June 8, 2021
-
BUSINESS FDA Approves Aducanumab, 1st Disease-Modifying Therapy for Alzheimer’s
June 8, 2021
-
BUSINESS Bristol Myers, Other Pharma Players Moving to Join Workplace Vaccination Campaign
June 7, 2021
-
BUSINESS Kobayashi Kako’s 116-Day Suspension Over, but No Timeline for Resumption
June 7, 2021
-
ACADEMIA As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
-
BUSINESS MSD Japan Spins Off Organon Women’s Health Biz, Ryota Sakurai Takes Helm
June 4, 2021
-
BUSINESS Astellas Plans to Cut 450 Jobs via Voluntary Redundancy Program
June 4, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…